Voorhees, P., D'Souza, A., Quach, H., Gaerditz, S., Carrillo-Cruz, E., Mielnik, M., Wróbel, T., Pianko, M., Kazandjian, D., Sidiqi, M. H., Stefano, V. D., Valdes, C. R., Midha, S., Grajales-Cruz, A., Goto, H., Ito, S., Cerchione, C., Jin, Z., Lee, S., Polepally, A., Rathi, S., Motte-Mohs, R. L., D'Amico, K., Doerr, T., Talati, C., Fleming, L. L., Ho, L., Weisel, K., Hus, M., Martínez-López, J. (2025). Etentamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study. Blood. https://doi.org/10.1182/blood-2025-247